{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:17:38Z","timestamp":1768000658493,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Biotechnology (DBT)","award":["BT\/PR7299\/MED\/29\/678\/2012"],"award-info":[{"award-number":["BT\/PR7299\/MED\/29\/678\/2012"]}]},{"DOI":"10.13039\/501100001332","name":"CSIR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001411","name":"ICMR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.03.027","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T22:07:30Z","timestamp":1521670050000},"page":"2293-2299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunotherapeutic potential of Leishmania ( Leishmania ) donovani Th1 stimulatory proteins against experimental visceral leishmaniasis"],"prefix":"10.1016","volume":"36","author":[{"family":"Keerti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narendra K.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Ratnapriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amogh A.","family":"Sahasrabuddhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Dube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.03.027_b0005","unstructured":"WHO. Leishmaniasis. http:\/\/wwwwhoint\/mediacentre\/factsheets\/fs375\/en\/; 2017."},{"key":"10.1016\/j.vaccine.2018.03.027_b0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0974-777X.62883","article-title":"Treatment of visceral leishmaniasis","volume":"2","author":"Moore","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.vaccine.2018.03.027_b0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?","volume":"2","author":"Freitas-Junior","year":"2012","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.vaccine.2018.03.027_b0020","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy\u2013challenges and opportunities","volume":"17","author":"Croft","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2018.03.027_b0025","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1038\/cti.2014.4","article-title":"Vaccines to prevent leishmaniasis","volume":"3","author":"Kumar","year":"2014","journal-title":"Clin Trans Immunol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fimmu.2014.00380","article-title":"Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches","volume":"5","author":"Joshi","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","author":"Gillespie","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.027_b0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0001-706X(00)00068-1","article-title":"Leishmania donovani in blood smears of asymptomatic persons","volume":"76","author":"Sharma","year":"2000","journal-title":"Acta Tropica"},{"key":"10.1016\/j.vaccine.2018.03.027_b0045","first-page":"22","article-title":"Vector control interventions for visceral leishmaniasis elimination initiative in South Asia, 2005\u20132010","volume":"136","author":"Picado","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2018.03.027_b0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1155\/2015\/176545","article-title":"Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B","volume":"26","author":"McQuarrie","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0055","article-title":"Decline in clinical efficacy of oral miltefosine in treatment of post Kala-azar Dermal Leishmaniasis (PKDL) in India","volume":"9","author":"Ramesh","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.03.027_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.03.027_b0065","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/1469-0691.12556","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"van Griensven","year":"2014","journal-title":"Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2018.03.027_b0070","doi-asserted-by":"crossref","unstructured":"Roatt BM, Aguiar-Soares RDO, Reis LES, Cardoso JMO, Mathias FAS, de Brito RCF, et al. A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden. Front Immunol 2017;8.","DOI":"10.3389\/fimmu.2017.00217"},{"key":"10.1016\/j.vaccine.2018.03.027_b0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/erv.13.23","article-title":"Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer","volume":"12","author":"Morrow","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.03.027_b0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0085","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3389\/fmicb.2016.01536","article-title":"The progress of therapeutic vaccination with regard to tuberculosis","volume":"7","author":"Cardona","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0090","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/21645515.2015.1119346","article-title":"A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB\/c mouse model of Chagas disease","volume":"12","author":"Barry","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.03.027_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1473-3099(05)70085-2","article-title":"Recombinant DNA-derived leishmania proteins: from the laboratory to the field","volume":"5","author":"Kubar","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.03.027_b0100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fmicb.2016.00312","article-title":"Comparative analysis of cellular immune responses in treated leishmania patients and hamsters against recombinant Th1 stimulatory proteins of Leishmania donovani","volume":"7","author":"Joshi","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0105","doi-asserted-by":"crossref","first-page":"e86073","DOI":"10.1371\/journal.pone.0086073","article-title":"Characterization of glycolytic enzymes\u2013rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis","volume":"9","author":"Gupta","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.03.027_b0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijpara.2012.02.013","article-title":"A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis","volume":"42","author":"Gupta","year":"2012","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0115","doi-asserted-by":"crossref","first-page":"e45766","DOI":"10.1371\/journal.pone.0045766","article-title":"Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis","volume":"7","author":"Kushawaha","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.03.027_b0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bbrc.2007.10.065","article-title":"Identification of leishmania fructose-1,6-bisphosphate aldolase as a novel activator of host macrophage Src homology 2 domain containing protein tyrosine phosphatase SHP-1","volume":"364","author":"Nandan","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2018.03.027_b0125","doi-asserted-by":"crossref","first-page":"932549","DOI":"10.4061\/2011\/932549","article-title":"Enolase: a key player in the metabolism and a probable virulence factor of trypanosomatid parasites-perspectives for its use as a therapeutic target","volume":"2011","author":"Avilan","year":"2011","journal-title":"Enzyme Res"},{"key":"10.1016\/j.vaccine.2018.03.027_b0130","first-page":"518","article-title":"The protective immunity of a DNA vaccine encoding Schistosoma japonicum Chinese strain triose-phosphate isomerase in infected BALB\/C mice","volume":"35","author":"Zhu","year":"2004","journal-title":"Southeast Asian J Trop Med Publ Health"},{"key":"10.1016\/j.vaccine.2018.03.027_b0135","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4049\/jimmunol.166.1.498","article-title":"Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning","volume":"166","author":"Probst","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.vaccine.2004.06.054","article-title":"Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis","volume":"23","author":"Garg","year":"2005","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2018.03.027_b0145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00436-005-1339-1","article-title":"Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models","volume":"96","author":"Dube","year":"2005","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2018.03.027_b0150","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/pmic.200600725","article-title":"Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes","volume":"7","author":"Gupta","year":"2007","journal-title":"Proteomics"},{"key":"10.1016\/j.vaccine.2018.03.027_b0155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2018.03.027_b0160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1099\/00222615-36-4-283","article-title":"Effect of bioamines on uptake of promastigotes of Leishmania donovani by hamster peritoneal macrophages","volume":"36","author":"Mitra","year":"1992","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0165","first-page":"179","article-title":"Tetrazolium (MTT) assay for cellular viability and activity","volume":"79","author":"Morgan","year":"1998","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jim.2011.02.004","article-title":"Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)","volume":"368","author":"Zivcec","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.03.027_b0175","doi-asserted-by":"crossref","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods (San Diego, Calif) 2001;25:402\u2013408.","DOI":"10.1006\/meth.2001.1262"},{"key":"10.1016\/j.vaccine.2018.03.027_b0180","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1128\/IAI.57.12.3770-3777.1989","article-title":"Amastigote stage-specific monoclonal antibodies against Leishmania major","volume":"57","author":"Jaffe","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.03.027_b0185","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1128\/AAC.42.10.2722","article-title":"Visceral leishmaniasis in the BALB\/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B","volume":"42","author":"Mullen","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.vaccine.2018.03.027_b0190","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.2042-7158.1988.tb05271.x","article-title":"The therapeutic effect of sodium stibogluconate in BALB\/c mice infected with Leishmania donovani is organ-dependent","volume":"40","author":"Carter","year":"1988","journal-title":"J Pharmacy Pharmacol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/imt.14.28","article-title":"Immunostimulatory effects of Leishmania infantum HSP70 recombinant protein on dendritic cells in vitro and in vivo","volume":"6","author":"Rasouli","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2018.03.027_b0200","first-page":"5","article-title":"Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages","author":"Rath","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0205","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.290.5495.1351","article-title":"Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies","volume":"290","author":"Kamhawi","year":"2000","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.vaccine.2018.03.027_b0210","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/IAI.57.10.3091-3096.1989","article-title":"Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters","volume":"57","author":"Gifawesen","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.03.027_b0215","doi-asserted-by":"crossref","first-page":"e0005011","DOI":"10.1371\/journal.pntd.0005011","article-title":"Immunotherapeutic potential of eugenol emulsion in experimental visceral leishmaniasis","volume":"10","author":"Islamuddin","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.03.027_b0220","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.4049\/jimmunol.145.12.4306","article-title":"Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide","volume":"145","author":"Liew","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0225","first-page":"2014","article-title":"Innate Immunity to leishmania infection: within phagocytes","author":"Lopes","year":"2014","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.vaccine.2018.03.027_b0230","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.03.027_b0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2018.03.027_b0240","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/jir461","article-title":"IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis","volume":"204","author":"Gautam","year":"2011","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T18:35:52Z","timestamp":1693593352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18303724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":48,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18303724"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic potential of Leishmania (Leishmania) donovani Th1 stimulatory proteins against experimental visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}